Elan recieves US patent for Alzheimer's treatment

Elan and Wyeth Pharmaceuticals, a division of Wyeth, today announced that the United States Patent and Trademark Office recently issued Neuralab Limited, a wholly owned subsidiary of Elan, three patents for the companies’ joint research on immunotherapeutic approaches to the treatment of Alzheimer’s disease.

The patents are for methods of prophylactically or therapeutically treating Alzheimer’s disease, including the administration of a pharmaceutical composition comprising an antibody that specifically binds to a region within the beta amyloid molecule.